Skip to content
Triangle logo TriangleGet started
← Melanoma

HEALTH PROFESSIONAL · SOURCE READING

Encorafenib

Source: Melanoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 2, 2025 · Captured 2026-09-09.

Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.

Context: Treatment Option Overview for Melanoma / Systematic Treatment for Unresectable Stage III, Stage IV, and Recurrent Disease / Signal transduction inhibitors / BRAF inhibitors

Encorafenib is an orally available, small-molecule, selective BRAF inhibitor. The FDA approved encorafenib in 2018 in combination with the MEK inhibitor binimetinib. A phase III randomized study demonstrated that encorafenib improved PFS and OS when compared with vemurafenib monotherapy.[27]

Source links and citations

Publication references

Read the original reference and check its publication notices.

Preserved source evidence · Not medical advice